NDASUBCUTANEOUSSOLUTION
Approved
Nov 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
REDITREX (methotrexate) by Nordic Pharma is reductase. Approved for rheumatoid arthritis, acute lymphoblastic leukemia. First approved in 2019.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REDITREX is a subcutaneous methotrexate solution approved in 2019 by Nordic Pharma for a broad range of oncologic and autoimmune indications. It works by inhibiting dihydrofolate reductase, disrupting DNA synthesis and cell replication in rapidly dividing cells including malignant tissues and immune cells. The mechanism in rheumatoid arthritis and psoriasis remains incompletely understood but involves immunosuppressive effects.
$0.076MPart D
PeakREDITREX is in peak commercial phase with modest Part D penetration ($76K annually), suggesting a niche or newly established position; teams may focus on indication expansion and market education rather than defensive growth.
Mechanism of Action
reductase. Dihydrofolates must be reduced to tetrahydrofolates by this enzyme before they can be utilized as carriers of one-carbon groups in the synthesis of purine nucleotides and thymidylate. Therefore, methotrexate interferes with DNA synthesis, repair, and cellular replication. Actively…
Indications (2)
Worked on REDITREX at Nordic Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.